中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2010年
30期
2123-2125
,共3页
肾上腺皮质腺癌%晚期%综合治疗%预后
腎上腺皮質腺癌%晚期%綜閤治療%預後
신상선피질선암%만기%종합치료%예후
Adrenal cortical adenocarcinoma%Advanced stage%Combined therapy%Prognosis
目的 分析晚期肾上腺皮质腺癌综合治疗的临床疗效.方法 回顾性分析了从1986-2006年间中国医学科学院肿瘤医院收治的12例晚期肾上腺皮质腺癌的综合治疗资料及随访结果,并复习相关文献.结果 在本组中,11例患者行手术治疗切除原发病灶,1例行活检术.术后11例行化疗或介入化疗,1例行放疗加化疗.病理及免疫组化:12例均为肾上腺皮质腺癌.按Jacques和Brennan分期法,本组病例均为临床Ⅳ期病例,其TNM分期为:T3N0M1:9例,T4N0M0:1例,T4N0M1:2例.12例病例均获随访,随访期为6个月～40个月.术后全身化疗,化疗有如下3种方案:顺铂+长春新碱+博莱霉素;环磷酰胺+长春新碱+博莱霉素;Taxol+顺铂.按1987年WHO统一的疗效评价标准评价,结果为:CR 0例,PR 7例,SD 3例,PD 2例.总的有效率为58.3%(7/12),中位无进展生存时间为9个月,中位生存期为个14月.结论 晚期肾上腺皮质腺癌尽量采取手术切除原发灶,术后辅以全身化疗或加局部介入化疗的综合治疗方法对提高晚期肾上腺皮质腺癌患者的生存率是有益的.对于骨转移病灶,放射治疗能缓解症状.
目的 分析晚期腎上腺皮質腺癌綜閤治療的臨床療效.方法 迴顧性分析瞭從1986-2006年間中國醫學科學院腫瘤醫院收治的12例晚期腎上腺皮質腺癌的綜閤治療資料及隨訪結果,併複習相關文獻.結果 在本組中,11例患者行手術治療切除原髮病竈,1例行活檢術.術後11例行化療或介入化療,1例行放療加化療.病理及免疫組化:12例均為腎上腺皮質腺癌.按Jacques和Brennan分期法,本組病例均為臨床Ⅳ期病例,其TNM分期為:T3N0M1:9例,T4N0M0:1例,T4N0M1:2例.12例病例均穫隨訪,隨訪期為6箇月～40箇月.術後全身化療,化療有如下3種方案:順鉑+長春新堿+博萊黴素;環燐酰胺+長春新堿+博萊黴素;Taxol+順鉑.按1987年WHO統一的療效評價標準評價,結果為:CR 0例,PR 7例,SD 3例,PD 2例.總的有效率為58.3%(7/12),中位無進展生存時間為9箇月,中位生存期為箇14月.結論 晚期腎上腺皮質腺癌儘量採取手術切除原髮竈,術後輔以全身化療或加跼部介入化療的綜閤治療方法對提高晚期腎上腺皮質腺癌患者的生存率是有益的.對于骨轉移病竈,放射治療能緩解癥狀.
목적 분석만기신상선피질선암종합치료적림상료효.방법 회고성분석료종1986-2006년간중국의학과학원종류의원수치적12례만기신상선피질선암적종합치료자료급수방결과,병복습상관문헌.결과 재본조중,11례환자행수술치료절제원발병조,1례행활검술.술후11례행화료혹개입화료,1례행방료가화료.병리급면역조화:12례균위신상선피질선암.안Jacques화Brennan분기법,본조병례균위림상Ⅳ기병례,기TNM분기위:T3N0M1:9례,T4N0M0:1례,T4N0M1:2례.12례병례균획수방,수방기위6개월～40개월.술후전신화료,화료유여하3충방안:순박+장춘신감+박래매소;배린선알+장춘신감+박래매소;Taxol+순박.안1987년WHO통일적료효평개표준평개,결과위:CR 0례,PR 7례,SD 3례,PD 2례.총적유효솔위58.3%(7/12),중위무진전생존시간위9개월,중위생존기위개14월.결론 만기신상선피질선암진량채취수술절제원발조,술후보이전신화료혹가국부개입화료적종합치료방법대제고만기신상선피질선암환자적생존솔시유익적.대우골전이병조,방사치료능완해증상.
Objective To analyze the clinical efficacy of combined therapy in the treatment of advanced adrenal cortical adenocarcinoma. Methods The clinical data of 12 cases with advanced adrenal cortical adenocarcinoma at our hospital from 1986-2006 were analyzed. And the relevant literatures were reviewed. Results Eleven patients underwent operation to remove primary lesions. Only 1 case received a biopsy. All cases were treated with chemotherapy or chemotherapy pulse post-operative radiotherapy. Pathological diagnosis was all of adrenal cortical adenocarcinoma. According to the staging criteria of Jacques and Brennan, all 12 cases were of Ⅳ stage. The follow-up duration was 6-40 months. According to evaluation criterion of chemotherapeutic effect by WHO in 1987, the results were; CR (complete remission) (n=0), PR (partial remission) (n=7), SD (stable disease) (n=3) and PD (progressive disease) (n=2). The effective rate was 58.3% (7/12). The median survival time was 14 months and median progression-free survival time 9 months. Conclusion Combined therapy of adrenal cortical adenocarcinoma is effective to prolong the patient lifespan. Radiotherapy offers partial symptomatic relief for those with osseous metastasis. Making an early diagnosis and offering a novel therapy yield a better outcome.
